Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.
Prednisolone was granted FDA approval on 21 June 1955.
Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.
Childrens Oncology Group, Philadelphia, Pennsylvania, United States
University Medical Center Goettingen, Goettingen, Germany
University Hospitals Bristol NHS Trust, Bristol, Avon, United Kingdom
Study site, Several, Germany
Study Site, Several, Spain
Pfizer Investigational Site, Bruxelles, Belgium
Groote Schuur Hospital, Cape Town, Western Cape, South Africa
Ninewells Hospital and Medical School, Dundee, Angus, United Kingdom
Chang Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan
Chang Gung Memorial Hospital - Chiayi, Chiayi County, Taiwan
Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung City, Taiwan
University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.